Latest Pharma and Biotech News
Pharmaceutical
12 June 2025 Artificial Intelligence (AI) has rapidly evolved from a promising technology to a core enabler of innovation in the pharmaceutical industry. Today, AI is estimated to generate between $350 billion and $410 billion in annual value for pharmaceutical companies.
Today's issue
Refine Search
Pharmaceutical
South Korean drugmaker JW Pharmaceutical has received regulatory approval in China for an injectable antibiotic made with its own synthesized active ingredient, marking a strategic expansion into the Asian market. 12 June 2025
Pharmaceutical
Artificial Intelligence (AI) has rapidly evolved from a promising technology to a core enabler of innovation in the pharmaceutical industry. Today, AI is estimated to generate between $350 billion and $410 billion in annual value for pharmaceutical companies. 12 June 2025
Biotechnology
The US Food and Drug Administration (FDA) yesterday approved Nuvation Bio’s Ibtrozi (taletrectinib), a kinase inhibitor, for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). 12 June 2025
Biotechnology
French biotech Enterome has secured $19 million in private funding to accelerate development of its OncoMimics immunotherapy platform, as it continues to show encouraging early signs of clinical activity across both solid and blood cancers. 12 June 2025
Biotechnology
California-based clinical-stage biotech Juvena Therapeutics has entered a global licensing and to discover, develop, and commercialize drug candidates that improve muscle health and body composition. 12 June 2025
Pharmaceutical
US biotech Novavax has reported that its experimental combination COVID-19 and influenza vaccine generated immune responses on par with approved shots in a descriptive Phase III trial involving older adults. The company said the results would help shape a future registrational study. 12 June 2025
Biotechnology
Biogen has highlighted the growing role of felzartamab in its pipeline during a virtual investor seminar, spotlighting three late-stage studies focused on rare kidney diseases and a broader strategy to expand into immune-mediated conditions. 12 June 2025
Pharmaceutical
Danish pharma major Novo Nordisk and privately-held Californian firm Deep Apple Therapeutics have announced a research collaboration and exclusive worldwide license agreement. 11 June 2025
Biotechnology
Switzerland-based Philochem and Bristol Myers Squibb radiopharma subsidiary RayzeBio have announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio. 11 June 2025
Pharmaceutical
The UK’s medicines regulator has released a suite of new guidelines to steer companies through its upcoming decentralized manufacturing framework, set to come into effect on July 23, 2025. 11 June 2025
Biotechnology
US clinical-stage biotech Oncolytics Biotech today announced the appointment of Jared Kelly as chief executive (CEO) and a member of its board of directors. 11 June 2025
Pharmaceutical
USA-based Insmed Incorporated closed Tuesday’s trading up by more than a third. 11 June 2025
Pharmaceutical
Italian family-owned drugmaker Chiesi Group and Sweden’s Key2Brain today announced a worldwide license agreement to advance the development of two blood-brain barrier (BBB)-crossing recombinant enzyme replacement therapies (ERT) for lysosomal storage disorders (LSD). 11 June 2025
Pharmaceutical
The UK government has doubled the rate that pharma companies must repay on the sales of newer products to the National Health Service (NHS) under the statutory scheme for branded medicines in the second half of 2025, to a record 31.3%. 11 June 2025
Biotechnology
South Korean biotech AriBio Co, specializing in neurodegenerative diseases, and a Swiss pharmaceutical company Acino, part of Arcera, a global life sciences company based in Abu Dhabi, announced an exclusive licensing and commercialization, and supply agreements for AR1001, an investigational oral therapy for Alzheimer’s disease. 11 June 2025
Biotechnology
Angelini Ventures has joined a syndicate of European life sciences investors to back Elkedonia, a French biotech developing a new class of neuroplastogens to treat depression and other neuropsychiatric conditions. 11 June 2025
Biotechnology
Germany-based Arvato and Dutch immunology specialist argenx have successfully achieved two important milestones in their European expansion. Following the launch of direct distribution for the Spanish market from Alcalá de Henares, the Italian market is now also being served from Arvato’s logistics site in Calcinate near Bergamo. 11 June 2025
Biotechnology
Boston, USA-based biotech Antares Therapeutics, launched yesterday with $177 million in Series A financing. 11 June 2025
Pharmaceutical
China-based biotech Innogen is making a strategic pivot toward international visibility following regulatory clearance of its first-in-class, ultra-long-acting GLP-1 receptor agonist for type 2 diabetes, alongside a move to go public on the Hong Kong Stock Exchange. 11 June 2025
Biotechnology
Belgian drugmaker UCB today announced new three-year data from Phase III trials, and their open-label extensions, investigating Bimzelx bimekizumab) in adults with active psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). 11 June 2025
All news
Pharmaceutical
South Korean drugmaker JW Pharmaceutical has received regulatory approval in China for an injectable antibiotic made with its own synthesized active ingredient, marking a strategic expansion into the Asian market. 12 June 2025
Pharmaceutical
Artificial Intelligence (AI) has rapidly evolved from a promising technology to a core enabler of innovation in the pharmaceutical industry. Today, AI is estimated to generate between $350 billion and $410 billion in annual value for pharmaceutical companies. 12 June 2025
Biotechnology
The US Food and Drug Administration (FDA) yesterday approved Nuvation Bio’s Ibtrozi (taletrectinib), a kinase inhibitor, for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). 12 June 2025
Biotechnology
French biotech Enterome has secured $19 million in private funding to accelerate development of its OncoMimics immunotherapy platform, as it continues to show encouraging early signs of clinical activity across both solid and blood cancers. 12 June 2025
Biotechnology
California-based clinical-stage biotech Juvena Therapeutics has entered a global licensing and to discover, develop, and commercialize drug candidates that improve muscle health and body composition. 12 June 2025
Pharmaceutical
US biotech Novavax has reported that its experimental combination COVID-19 and influenza vaccine generated immune responses on par with approved shots in a descriptive Phase III trial involving older adults. The company said the results would help shape a future registrational study. 12 June 2025
Biotechnology
Biogen has highlighted the growing role of felzartamab in its pipeline during a virtual investor seminar, spotlighting three late-stage studies focused on rare kidney diseases and a broader strategy to expand into immune-mediated conditions. 12 June 2025
Pharmaceutical
Danish pharma major Novo Nordisk and privately-held Californian firm Deep Apple Therapeutics have announced a research collaboration and exclusive worldwide license agreement. 11 June 2025
Biotechnology
Switzerland-based Philochem and Bristol Myers Squibb radiopharma subsidiary RayzeBio have announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio. 11 June 2025
Pharmaceutical
The UK’s medicines regulator has released a suite of new guidelines to steer companies through its upcoming decentralized manufacturing framework, set to come into effect on July 23, 2025. 11 June 2025
Biotechnology
US clinical-stage biotech Oncolytics Biotech today announced the appointment of Jared Kelly as chief executive (CEO) and a member of its board of directors. 11 June 2025
Pharmaceutical
USA-based Insmed Incorporated closed Tuesday’s trading up by more than a third. 11 June 2025
Pharmaceutical
Italian family-owned drugmaker Chiesi Group and Sweden’s Key2Brain today announced a worldwide license agreement to advance the development of two blood-brain barrier (BBB)-crossing recombinant enzyme replacement therapies (ERT) for lysosomal storage disorders (LSD). 11 June 2025
Pharmaceutical
The UK government has doubled the rate that pharma companies must repay on the sales of newer products to the National Health Service (NHS) under the statutory scheme for branded medicines in the second half of 2025, to a record 31.3%. 11 June 2025
Biotechnology
South Korean biotech AriBio Co, specializing in neurodegenerative diseases, and a Swiss pharmaceutical company Acino, part of Arcera, a global life sciences company based in Abu Dhabi, announced an exclusive licensing and commercialization, and supply agreements for AR1001, an investigational oral therapy for Alzheimer’s disease. 11 June 2025
Biotechnology
Angelini Ventures has joined a syndicate of European life sciences investors to back Elkedonia, a French biotech developing a new class of neuroplastogens to treat depression and other neuropsychiatric conditions. 11 June 2025
Biotechnology
Germany-based Arvato and Dutch immunology specialist argenx have successfully achieved two important milestones in their European expansion. Following the launch of direct distribution for the Spanish market from Alcalá de Henares, the Italian market is now also being served from Arvato’s logistics site in Calcinate near Bergamo. 11 June 2025
Biotechnology
Boston, USA-based biotech Antares Therapeutics, launched yesterday with $177 million in Series A financing. 11 June 2025
Pharmaceutical
China-based biotech Innogen is making a strategic pivot toward international visibility following regulatory clearance of its first-in-class, ultra-long-acting GLP-1 receptor agonist for type 2 diabetes, alongside a move to go public on the Hong Kong Stock Exchange. 11 June 2025
Biotechnology
Belgian drugmaker UCB today announced new three-year data from Phase III trials, and their open-label extensions, investigating Bimzelx bimekizumab) in adults with active psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). 11 June 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze